Novo’s Long-Term Strategy Fails to Calm Investors

Novo Nordisk shares came under heavy pressure Monday after the Danish drugmaker unveiled a long-term strategy aimed at rebuilding growth in the weight-loss market. The company’s Copenhagen-listed shares dropped 7.7%, marking their worst daily performance since February as investors remained concerned about the competitive pressures facing the business.

Novo said it plans to launch more than five drugs with “multi-blockbuster” potential by 2030 and generate more than 150 billion Danish kroner, equivalent to about $23 billion, in risk-adjusted pipeline sales by 2035. The targets include existing assets and are intended to create a broader growth base beyond the company’s current weight-loss franchise.

Diversification Becomes a Strategic Priority

Chief Executive Officer Mike Doustdar emphasized the need for Novo to become a more diversified pharmaceutical company. The company expects revenue growth between 2026 and 2030 to broadly match the growth rates of major pharmaceutical peers, including Eli Lilly, AstraZeneca, Amgen, Biogen, Merck, AbbVie and Novartis.

The strategy reflects a shift in focus from relying heavily on the success of semaglutide-based medicines toward building a wider portfolio of growth products. For investors, however, the immediate question is how quickly those new medicines can contribute meaningful revenue while the company manages increasing competition in its core market.

Semaglutide Patent Expiration Looms

One of the biggest challenges facing Novo is the approaching loss of key patent exclusivity for semaglutide, the active ingredient in Wegovy and Ozempic. The patent is set to expire in the United States in 2032, making the issue particularly important because the U.S. represented more than half of Novo’s overall sales last year.

Doustdar described the patent expiration as the central issue facing investors, while also acknowledging that Novo helped create an increasingly attractive market that has drawn competitors from across the pharmaceutical industry. The resulting competition is expected to increase pressure on pricing and market share.

Competition Changes the Weight-Loss Market

Novo’s success with Wegovy and Ozempic helped establish the modern anti-obesity drug market, but the same opportunity has attracted major pharmaceutical companies. The company now faces the challenge of defending its existing franchise while simultaneously developing the next generation of products.

The pressure is reflected in investor expectations. Novo’s latest targets provide a longer-term roadmap, but they do not offer an immediate solution to slowing momentum or intensifying competition. The company’s ability to execute its diversification strategy will therefore be central to how markets assess its growth prospects.

What Investors May Watch Next

Novo’s next phase will depend on whether its pipeline can produce commercially significant medicines before the loss of semaglutide exclusivity becomes a larger financial issue. Investors are likely to focus on clinical progress, new product launches, competitive developments and the pace at which the broader portfolio can offset potential pricing pressure on Wegovy and Ozempic. The strategy sets a long-term direction, but execution will determine whether Novo can emerge as a larger and more diversified company.